


Analysis of Her-Tox binding to Her2 receptor

**FIG. 1**




FIG. 2

Anti-Her2 variant expression test

Anti-Her2 Variant Expression



FIG. 3

Proliferation Assay with HCC 1954 Breast Cancer Line and Dolastatin Linker Derivative




FIG. 4

Proliferation Assay with HCC 1954 Breast Cancer Line and Her-tox conjugates




FIG. 5

Proliferation Assay with SKOV-3 Ovarian Cancer Line and Dolastatin Linker Derivatives




FIG. 6

Proliferation Assay with SKOV-3 Ovarian Cancer Line and Her-tox conjugates




FIG. 7

**Proliferation Assay with MDA-MB-468 Breast Cancer
Line and Dolastatin Linker Derivatives**




FIG. 8

Proliferation Assay with MDA-MB-468 Breast Cancer Line and Her-tox Conjugates





FIG. 9

**FIG. 10**

Assay Formats Used to Measure HER2-linked Dolastatin Derivative Concentration in SD Rat Serum

Small Molecule(SM)- Dolastatin




FIG. 11

**Rat PK Results: Serum concentrations of Transtuzumab-Linked
Dolastatin Derivatives**




FIG. 12

Rat PK data with Trastuzumab-Linked Dolastatin Derivatives




FIG. 13

In vivo stability measurements detecting at least two dolastatin derivatives linked to transtuzumab




FIG. 14

Rat PK data with Trastuzumab -Linked Dolastatin Derivatives

HCC1954-e202 Group Mean Summary Data (TV = 1000 mm³ or Day 60)




FIG. 15

Anti-tumor Efficacy of Trastuzumab-linked Derivatives






FIG. 16

Anti-tumor Efficacy of Dolastatin Linker Derivatives**FIG. 17**

Anti-tumor Efficacy of Dolastatin Linker Derivatives**FIG. 18**